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Abstract: The use of multi drug regimens among the elderly population has increased 
tremendously over the last decade although the benefits of medications are always accompanied 
by potential harm, even when prescribed at recommended doses. The elderly populations are 
particularly at an increased risk of adverse drug reactions considering comorbidity, poly-therapy, 
physiological changes affecting the pharmacokinetics and pharmacodynamics of many drugs 
and, in some cases, poor compliance due to cognitive impairment and/or depression. In this 
setting, drug–drug interaction may represent a serious and even life-threatening clinical condi-
tion. Moreover, the inability to distinguish drug-induced symptoms from a definitive medical 
diagnosis often results in addition of yet another drug to treat the symptoms, which in turn 
increases drug–drug interactions. Cognitive enhancers, including acetylcholinesterase inhibitors 
and memantine, are the most widely prescribed agents for Alzheimer’s disease (AD) patients. 
Behavioral and psychological symptoms of dementia, including psychotic symptoms and 
behavioral disorders, represent noncognitive disturbances frequently observed in AD patients. 
Antipsychotic drugs are at high risk of adverse events, even at modest doses, and may interfere 
with the progression of cognitive impairment and interact with several drugs including anti-
arrhythmics and acetylcholinesterase inhibitors. Other medications often used in AD patients 
are represented by anxiolytic, like benzodiazepine, or antidepressant agents. These agents also 
might interfere with other concomitant drugs through both pharmacokinetic and pharmaco-
dynamic mechanisms. In this review we focus on the most frequent drug–drug interactions, 
potentially harmful, in AD patients with behavioral symptoms considering both physiological 
and pathological changes in AD patients, and potential pharmacodynamic/pharmacokinetic 
drug interaction mechanisms.
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Introduction
A potential drug interaction is defined as an event in which two drugs known to interact 
were concurrently prescribed, regardless of whether adverse events occurred.1 Drug 
interactions may have potentially life-threatening consequences, especially in frail 
elderly subjects.2 Indeed, the elderly are particularly at an increased risk of adverse 
drug reactions (ADRs) considering comorbidity and the consequent poly-therapy 
as well as the age related changes of pharmacokinetics and pharmacodynamics of 
many drugs and, in some cases, the poor compliance due to cognitive impairment or 
behavior alteration.3,4 The use of multi drug regimens among the elderly population 
has increased tremendously over the last decade although the benefits of medications 
are always accompanied by potential harm (eg, adverse reaction due to drug–drug 
interaction), even when prescribed at recommended doses.2,3 An ADR is not always 
easy to recognize, especially in the elderly, in whom many clinical conditions coexist. 
Indeed, an ADR may be much more easily ascribed to “frailty” itself, an already existing 
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diagnosis or the onset of a new clinical problem rather than 
to a pharmacological adverse effect. For example, falls, 
delirium, drowsiness, lethargy, light-headedness, apathy, 
urinary incontinence, chronic constipation, and dyspepsia 
are frequently accepted as a primary diagnosis rather than 
a potential ADR.5 The inability to distinguish drug-induced 
symptoms from a definitive medical diagnosis often results in 
the addition of another drug to treat the symptoms increasing 
the risk of drug–drug interactions.5 
Alzheimer’s disease (AD) is the most common neuro-
degenerative disorder with a huge prevalence in the elderly 
population. This clinical condition is characterized by a slow 
progressive impairment of cognitive function.6 Psychiatric 
and behavioral symptoms are common in patients with AD 
and contribute substantially to the morbidity of the illness.7–9 
Delusions or hallucinations appear in 30%–50% of AD 
patients and, as many as 70% of them exhibit agitated or 
aggressive behaviour.8 Considering the late onset of the 
syndrome, AD patients are often co-affected by other age-
related diseases such as systemic hypertension, heart disease, 
dyslipidemia, diabetes, arthritis, renal failure, endocrine 
alteration, neoplasm etc, and, consequently, receive several 
drugs.10,11 For a variety of reasons (eg, increased sensitivity 
to certain adverse effects, potential difficulty with adhering 
to a regimen, reduced ability to recognize and report adverse 
events) the risk of ADR may be less favorable in AD patients 
as compared to those without dementia.12,13
Generally, Alzheimer patients with mild-to-severe 
disease are treated by cognitive enhancers like acetylcho-
linesterase inhibitors (AChEIs) and memantine with the 
intent to decrease the rate of disease progression.14 More-
over, AD patients with behavioral symptoms need specific 
treatments such as psychotherapy and, when symptoms 
are not controlled, pharmacotherapy. As recommended 
by several authors, non-pharmacological interventions 
(eg, psychosocial/psychological counseling, interpersonal 
management, and environmental management) should 
be the first strategy and, when ineffective, it should be 
combined with specific drug classes for the shortest time 
possible. In particular, the most represented medications 
are first- and second-generation antipsychotic drugs.13,15–19 
These medications present a high risk of adverse events, 
even at modest doses, and may favor the progression of 
cognitive impairment.20–22 Moreover, antipsychotics may 
interact with several drugs including antiarrhythmics and 
AChEIs.23,24 Long-term studies of efficacy and safety of 
antipsychotics in elderly patients have been limited in 
number, and some evidences suggest that antipsychotic 
drugs could be related with cardiovascular events (strokes 
and heart arrhythmia).25–30 In this review we focus on the 
most frequent drug–drug interactions, potentially harmful, 
in AD patients with behavioral symptoms. The potential 
pharmacodynamic/pharmacokinetic drug interaction 
mechanisms are also analyzed.
Alzheimer patient-associated 
alterations affecting drug 
pharmacokinetics and 
pharmacodynamics 
Pharmacokinetics is the study of drug absorption, distribu-
tion, metabolism, and excretion. Drug pharmacokinetics is 
affected by several conditions related to the patients, such as 
genetic determinants and age related alterations.1 Considering 
the late onset of AD, the major pharmacokinetic alteration 
of drugs, observed in Alzheimer patients, is similar to those 
described in the elderly population. The most important 
age-related processes, observed also in healthy old people, 
are related to muscle structure, liver and kidney function.31,32 
In elderly patients, muscle mass and total body water are 
reduced33 affecting pharmacokinetics of hydrophilic drugs 
with a smaller volume of distribution. Conversely, body fat 
increases from 20% to 40% with age,34,35 resulting in a larger 
volume of distribution of lipophilic drugs. The distribution 
of drugs into the central nervous system (CNS) tissue might 
be affected in the elderly considering that the blood–brain 
barrier becomes more porous in the elderly, resulting in drug 
availability to the CNS being increased.36 Moreover, in the 
elderly, an age-related decrease in the apparent liver blood 
flow has been reported.37,38 As a consequence, both total drug 
clearance and free drug clearance can decrease. However, 
the most significant organ changes in the elderly occur in the 
aging kidneys where a glomerulus loss is accompanied by a 
decrease in renal plasma flow.39 
Pharmacodynamics is the study of the time course and 
intensity of drugs’ pharmacologic effects. Pharmacodynamic 
interactions involve changes in a drug action on a receptor 
or a biologically active site.1 At pharmacodynamics level, 
although the biologic mechanisms in many cases are not 
well explained, elderly patients are particularly vulnerable to 
adverse effects related to CNS drugs, such as antipsychotics, 
including delirium, extrapyramidal symptoms, arrhythmias, 
and postural hypotension.40 Moreover, several age-related 
diseases increase the sensitivity to drug effects and lower 
the susceptibility threshold for drug-related adverse effects, 
independently of their mechanisms. For example, ageing is 
associated with increased sensitivity to the CNS effects of 
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benzodiazepines:41,42 sedation is induced by diazepam at lower 
doses and lower plasma concentrations in elderly subjects.43,44 
Ageing is also associated with increased sensitivity to the 
effects of nitrazepam, flurazepam, and loprazolam,45,46 but the 
exact mechanisms responsible for the increased sensitivity to 
benzodiazepines are unknown. Moreover, the elderly present 
a response to postural changes different from young subjects; 
indeed, cardiac output is maintained by increasing heart rate 
in the young, while in elderly subjects it is maintained by an 
increased stroke volume.41 These age related changes make 
the elderly more susceptible to the effects of drugs affect-
ing cardiac rhythm or vasculature, as well as vagomimetic 
or antihypertensive drugs, resulting in an increased risk of 
hypotension episodes.41
However, if the pharmacokinetic changes in Alzheimer 
patients generally resemble those observed in the elderly 
population and several predisposing factors for ADR and 
drug–drug interactions are present among the normal 
elderly population, the pharmacodynamics of some CNS 
drugs may differ between normal elderly and Alzheimer 
patients. Indeed, AD selectively damages brain regions and 
neurotransmission pathways and is characterized by the pres-
ence of amyloid beta plaques and neurofibrillary tangles.47 
Recent radiologic studies have shown that neuronal death 
is limited in normal aging, while in AD there is consider-
able neuronal loss.47,48 The latter is a constant feature and 
eventually the direct cause of dementia. Interestingly, the 
distribution of the pathological features of AD seems to 
follow a region-specific pattern: the amyloid plaques are 
more prevalent in the neocortex and the neuronal/synaptic 
loss is more represented in the hippocampus, posterior cingu-
late, and corpus callosum areas of the brain closely involved 
with memory formation and higher cortical activities.49–52 
These pathological anatomical alterations underline a more 
complex modification in neurotransmission resulting in a 
reduction of the cholinergic transmission. The cholinergic 
system plays a fundamental role not only in the cognitive 
processes of dementia, but also in the behavioral symptoms 
associated with AD. Alterations in the cholinergic system 
can cause symptoms such as apathy, affective disorders, 
psychomotor impairment, agitation, and psychosis.53,54 
Although the impaired neurotransmission in AD patients 
represents the major pharmacological target (especially 
cholinergic system) for disease treatment, it might also 
represent a point of weakness for AD patients, especially 
for those with behavioral symptoms, increasing CNS drug 
activity or sensitivity and thus favoring ADR and/or negative 
pharmacodynamic drug–drug interaction.
Pharmacokinetic drug interaction 
Cognitive enhancers, including AChEIs and memantine, are 
the most widely prescribed agents for AD patients. The US 
Food and Drug Administration (FDA) has approved gal-
antamine and rivastigmine for mild-to-moderate dementia, 
memantine for moderate-to-severe dementia, and donepezil 
for mild-to-severe dementia.55,56 Although these drugs did not 
present frequent pharmacokinetic drug interactions, in some 
cases they may occur. In the following section, we describe 
the major drug–drug interactions of AD pharmacological 
treatments. By definition, pharmacokinetic interactions 
involve alterations in the plasma concentration of a drug by 
a second agent that affects absorption, distribution, metabo-
lism, and elimination phases.1 
ACheIs
As pharmacological class, AChEIs have relatively few phar-
macokinetic interactions. However, considering that done-
pezil and galantamine are metabolized in the liver through 
CYP2D6 and CYP3A4, their hepatic metabolism may be 
affected by specific substrates, inhibitors, or enhancers of 
the same enzymes.57 Several drugs, reported in Table 1, 
may potentially interact with donepezil and galantamine at 
this level with different mechanisms: 1) by direct enzyme 
inhibition (eg, ketoconazole strongly inhibits CYP3A4 by 
non-competitive mechanism) and 2) competing for the cata-
lytic site of the enzyme CYP3A4 (eg, benzodiazepines are 
metabolized by CYP3A4 cytochrome thus reducing the rate 
of transformation of the concurrent drugs eliminated by the 
same enzyme such as donepezil).58 Tiseo et al documented 
that in healthy humans the concurrent administration of keto-
conazole and donepezil produces no change in ketoconazole 
plasma concentrations, but a statistically significant change 
in donepezil plasma concentrations.59 However, given that 
donepezil may be metabolized by two cytochromes (CYP3A4 
and CYP2D6), the competitive inhibition with other CYP2D6 
or CYP3A4 drug substrates, such as antidepressant or ben-
zodiazepine, may not be clinically relevant. Interestingly, 
the oral coadministration of once-daily donepezil 5 mg for 
15 days and once-daily oral sertraline (50 mg for 5 days 
increased to 100 mg for 10 days) did not result in any clini-
cally significant pharmacokinetic interactions, and no unex-
pected ADRs were observed in healthy humans.60 Instead, 
the coadministration of galantamine with ketoconazole 
(CYP3A4 strong inhibitor) or paroxetine (CYP2D6 strong 
inhibitor) leads to a 30% and 40% increase, respectively, 
in galantamine exposure, compared to galantamine alone.61 
The exposure to galantamine in patients with moderate and 
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severe renal impairment is significantly higher than in healthy 
subjects, and is further approximately 30% higher in patients 
with moderate hepatic impairment.61,62 Therefore, attention 
should be paid when galantamine is coadministered with 
other drugs in patients with renal or hepatic impairment.
The competitive drug–drug interaction for the CYP may 
become clinically significant also in the elderly where an age-
related reduced hepatic and renal clearance (see “AChEIs” 
section) has been observed. It is noteworthy that rivastig-
mine, another AChEI, is least likely among the cognitive 
enhancers to have pharmacokinetic interactions with other 
medications since it does not undergo hepatic metabolism. 
Grossberg et al reported that rivastigmine did not lead to 
increased adverse events when administered concomitantly 
with 22 different classes of medications, including antidi-
abetic, cardiovascular, gastrointestinal, and nonsteroidal 
Table 1 List of important drugs that are substrates or inhibitors of cytochromes CYP2D6 and CYP3A4
Substance name CYP2D6 Substance name CYP3A4
Substrates Inhibitors  Substrates Inhibitors
Amiodarone + Albuterol +
Aripiprazole + + Alprazolam +
Bupropion + + Amiodarone + +
Cimetidine + + Aripiprazole +
Citalopram + Atorvastatin + +
Donepezil + Betamethasone +
Duloxetine + Buspirone +
Fluoxetine + + Carbamazepine +
Galantamine + Chlordiazepoxide +
Haloperidol + + Citalopram +
Levomepromazine + + Cortisol +
Melperone + Diazepam +
Metoclopramide + Diltiazem + +
Moclobemide + Donepezil ±
Norfluoxetine + + enalapril +
Paroxetine + erythromycin + +
Pergolide + escitalopram +
Perphenazine + estrogens +
Propafenone + etoricoxib +
Propranolol + + Finasteride +
Sertraline + Fluconazole +
Thioridazine + Fluvoxamine ± +
Trazodone + + Galantamine +
Tricyclic antidepressants + Grapefruit juice* +
venlafaxine + Haloperidol + +
Fluphenazine + Isosorbide +
Risperidone + Itraconazole + +
Itraconazole + +
Ketoconazole + +
Lansoprazole +
Mirtazapine + ±
Nefazodone + +
Nifedipine + +
Quetiapine +
Raloxifene + +
Sertraline ± +
Simvastatin + +
Trazodone + ±
Triazolam +
Tricyclic antidepressants + +
Zolpidem +
Note: Data from Hiemke,68 Bressler,96 Ingelman-Sundberg,97 Zhou et al.98 ±, weak inhibitory or inducing effect; +, significant inhibitory or inducing effect.
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anti-inflammatory drugs in Alzheimer patients enrolled in 
a prospective study.63
Memantine
Memantine is a weak base with a pKa of 10.27 and it is 
predominantly excreted unchanged by the kidneys.64 Urine 
pH has been shown to be a major determining factor for 
the excretion of alkaline drugs like memantine, reduc-
ing the excreted amount.65 In this setting, Freudenthaler 
et al demonstrated a considerable effect of urine pH of 
healthy volunteers on memantine excretion.66 Since the 
renal excretion of memantine may have a relevant impact 
on the pharmacokinetic profile, changing of dietary habits 
that may alter urine pH should be avoided during treatment 
with such agent. Marked changes of urine pH might lead to 
tissue memantine overexposure resulting in toxic effects, 
especially in the elderly, where a reduced renal function 
has been described. Moreover, increased plasma levels of 
memantine may arise if coadministered with agents using the 
same renal cationic transport system as amantadine, such as 
cimetidine, ranitidine, procainamide, quinidine, quinine, and 
nicotine.67 Serum hydrochlorothiazide levels may be reduced 
by coadministration with memantine, and patients treated 
with warfarin should be monitored for possible increases in 
international normalized ratio or prothrombin time.67
Miscellaneous
Other pharmacokinetic drug–drug interactions that may 
occur in Alzheimer patients are related to psychiatric drugs 
such as benzodiazepine, antidepressant, and antipsychotic 
agents that are largely used in such patients, especially 
for behavioral alterations. In this setting, the major part of 
pharmacokinetic drug–drug interactions is related to hepatic 
metabolism (Table 1). For example, hepatic CYP enzymes 
of the phase 1 metabolism are most susceptible, regarding 
the pharmacokinetic interactions of antipsychotic drugs.24 
Among the multiple isoenzymes in the liver, CYP1A2, 
CYP2C19, CYP2D6, and CYP3A4 are practically relevant 
for the degradation of antipsychotic drugs.68 Coadministration 
of an antipsychotic drug with paroxetine, a potent inhibitor 
of CYP2D6, may lead to elevated plasma concentrations 
of the antipsychotic drug, and thus enhance concentration-
dependent side effects such as extrapyramidal symptoms.57 
Other pharmacokinetic drug–drug interactions that may occur 
in patients are represented by hepatic enzyme induction, thus 
resulting in reduced tissue exposure and/or drug failure. In 
the clinical setting, the most important inducers of CYP1A2 
are polycyclic aromatic hydrocarbons that are present in 
cigarette smoke. For CYP3A4, carbamazepine is the most 
important inducer.69,70 As example, a susceptible substrate of 
CYP3A4 is represented by quetiapine; it was described that 
quetiapine plasma concentration decreases by approximately 
90% when coadministered with carbamazepine.69,70 Inducer 
enzyme drugs that may affect the pharmacokinetics of other 
drugs are listed in Table 2.
Pharmacodynamic drug interaction 
Pharmacodynamic drug–drug interactions may result from 
an antagonistic or synergistic mechanism. Several CNS 
drugs may interact directly at the receptor level or indi-
rectly affecting one or more neurotransmission system. In 
particular, the risk to develop an ADR related to a negative 
drug–drug interaction is increased in the elderly due to CNS 
ageing alterations and may be more relevant in Alzheimer 
patients (see the previous section). The cholinergic theory of 
AD71 has led to development of the cholinesterase inhibitors. 
When used appropriately, these medications may slow the 
decline in cognition and functional impairment associated 
with AD. However, based on their opposing mechanisms 
of action, concomitant use of cholinesterase inhibitors and 
anticholinergics may result in pharmacological antagonism 
(Figure 1).72 
Cholinergic antagonism
The anticholinergic effect is a feature of several drugs such as 
antipsychotics, antidepressants, antihistamines, bronchodila-
tors, drugs for urinary incontinence etc. There is evidence 
that the use of these classes of drugs, even in non-Alzheimer 
elderly individuals, is considered potentially inappropriate73 
and the use of anticholinergics by those with dementia is 
especially troubling because these individuals are more prone 
to develop medication-induced cognitive impairment.73 It is 
noteworthy to mention that tertiary anticholinergics such 
as atropine have been successfully used as an antidote for 
Table 2 Principal CYP3A4 inducer drugs
Drug name
Carbamazepine
efavirenz
Dexamethasone
Lovastatin
Oxybutynin
Rifabutin
Rifampicin
Phenobarbital
Phenytoin
Primidone 
Note: Data from Spina et al,57 Hiemke,68 Ingelman-Sundberg,97 Zhou et al.98
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donepezil over-dosage,74 and concomitant use of anticholin-
ergics was not allowed in randomized placebo-controlled tri-
als of AChEIs.75–77 As shown by Roe et al the concomitant use 
of AChEIs and anticholinergic drugs is quite frequent in the 
Alzheimer population.72 Indeed, they found that community-
based elderly individuals with probable dementia are more 
likely to take anticholinergics than controls. Patients taking 
donepezil frequently use an anticholinergic medication con-
comitantly. In particular, they found that 33% of those taking 
donepezil also were receiving anticholinergics, compared 
with 23% of controls and 26% of all patients in the study 
used multiple anticholinergic medications. Similar results 
were obtained by Carnahan et al in a cross-sectional study to 
measure the prevalence of anticholinergic drug use in patients 
receiving cholinesterase inhibitors and to describe change in 
use of anticholinergics upon inception of AChEI treatment.78 
They showed that the concurrent use of anticholinergics and 
AChIs in this cohort reaches 35%. Also Robinson et al, in an 
Australian naturalistic study, highlights that co-prescribing 
of cholinesterase inhibitors and drugs with anticholinergic 
activity is a common practice and is similar to that seen 
in other developed countries.79 An interesting survey on 
AChEIs’ negative drug–drug interaction was performed by 
Tavassoli et al.80 Analyzing the spontaneous reported ADRs 
related to AChEIs in France up to 2006, they found that the 
most frequently reported ADRs, due to drug–drug interac-
tion, in patients treated with AChEIs were associated with 
bradycardia (54.5%) and anticholinergic (31.4%) drugs, 
in most cases via pharmacodynamic mechanisms. ADRs 
due to drug–drug interactions were mainly represented by 
cardiovascular (bradycardia, atrioventricular block [AVB] 
and arterial hypotension) and neurological (mainly mental 
confusion) events.80 
In order to evaluate the impact of the atypical antipsychot-
ics, olanzapine, quetiapine, and risperidone on cognition in 
patients with AD, Vigen et al carried out a clinical study in 
421 AD outpatients with psychosis or agitated/aggressive 
behavior, randomized to masked, flexible-dose olanzapine, 
quetiapine, risperidone or placebo.21 Patients were followed 
for 36 weeks and cognitive assessments were obtained at 
baseline, 12 weeks, 24 weeks, and 36 weeks. Approximately 
60% of those patients were treated concomitantly with 
AChEIs. The authors found that, in this cohort, atypical 
antipsychotics were associated with worsening cognitive 
function compared with placebo.21 Anticholinergic related 
drug effects, as well as those described for antipsychotic 
agents, can counteract AChEIs’ beneficial effect. Considering 
that anticholinergic drugs can worsen cognitive impairment, 
they should be administered with caution in elderly patients, 
especially in AD. The development of an adverse outcome 
when a demented patient is exposed to anticholinergic drugs, 
may depend mainly on two factors: total anticholinergic load 
(ie, use of multiple drugs with anticholinergic activity or use 
of high doses of these products), and individual pharmacoki-
netic and pharmacodynamic variability.72 Overall, the con-
current use of anticholinergics and AChEIs is quite common 
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Figure 1 Pharmacodynamic drug–drug interaction in a cholinergic synapse: acetylcholinesterase inhibitor (ACheI) and anti-muscarinic drug. 
Notes: The concomitant administration of ACheIs (green triangles) and anticholinergic drugs may result in a pharmacodynamic interaction in the synapse where the 
beneficial increment of acetyl-choline (blue circle), related to AChE (blue triangles) inhibition, is at least partially reversed by anti-muscarinic drugs (red ellipse) at receptor 
levels (blue bars).
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in a clinical setting but is rarely appropriate considering the 
pharmacologic antagonism.72
Potential ADR at cardiovascular level
Most of the cardiovascular ADRs to AChEIs might be related 
to stimulation of the parasympathetic nervous system.81 
The parasympathetic nervous system can affect heart as 
well as brain function, and its effect on the heart is more 
complicated than is generally thought.81 Arrhythmia and 
syncope have been reported with the use of AChEIs. The 
heart is naturally rich with cholinesterase, and its inhibition 
may affect cardiac function, especially in elderly patients, 
many of whom have concomitant cardiovascular disease. 
The inhibition of cholinesterase by AChEIs retards acetyl-
choline degradation and potentiates the cardio-inhibitory 
effect.81 Moreover, AChEIs increase arterial blood pres-
sure through central M1 and M2 subtypes of muscarinic 
receptors.80 However, the effect of AChEIs is only slight in 
patients who receive a typical dose. Morganroth et al pooled 
data from four large placebo-controlled trials in order to 
assess possible electrocardiogram (ECG) changes associ-
ated with rivastigmine.82 The authors determined that the 
incidence of first-degree AVB and bradycardia were higher 
in the rivastigmine higher dose group when compared with 
the lower dose and placebo groups, although this difference 
did not reach statistical significance. A higher incidence 
of first-degree AVB, increased PR intervals, or decreased 
heart rates was also found in two trials assessing the safety 
of donepezil in Alzheimer patients with or without the use 
of cardiac-related drugs, also in this case, the results were 
not statistically significant.82,83 Although the relationship 
of bradycardia and syncope with AChEIs remains unclear, 
there is an increasing number of case reports suggesting a 
causal relationship.84–86 The cardiovascular effects reported 
for AChEIs and the underlying molecular mechanisms may 
explain most of the negative drug–drug interactions with 
other drugs with cardiac activity.
In last few years, there have also been concerns regarding 
the mortality risk of antipsychotics in people with demen-
tia. The FDA conducted a meta-analysis based on 17 of 
the short-term atypical antipsychotics in people with AD, 
highlighting a significant increase in mortality risk for 
individuals treated with atypical antipsychotics compared 
to individuals receiving placebo, leading to a “black box” 
warning regarding mortality risk.87 Five meta-analyses on 
antipsychotic drugs reported a significantly increased risk 
of cerebrovascular events with atypical antipsychotics com-
pared to placebo.88–93 These findings should be interpreted 
considering that antipsychotic drugs might present a direct 
effect on the development of cardiovascular events such as 
QT prolongation,24 that could be worsened by drug–drug 
interactions. In particular, QTc interval prolongation is 
reported for a number of old and new antipsychotic drugs, 
such as, haloperidol, levomepromazine, melperone, pimozide, 
quetiapine, sertindole, thioridazine, or ziprasidone.94–96 When 
an antipsychotic drug affecting QTc prolongation is combined 
with another QTc-lengthening drug or drugs slowing cardiac 
frequency (AChEIs), the concomitant use may have additive 
or even potentiating effects.67 Moreover, as suggested by 
Pariente et al,88 we can hypothesize that antipsychotic effects, 
both on body weight and metabolic syndrome development, 
seem unlikely in the context of Alzheimer patients. In this 
setting, if such a pathway is involved, one would expect an 
over-time progressive increasing risk rather than, as they 
found, a transient acute risk that decreases thereafter only.
Memantine
With respect to drug–drug interactions related to memantine 
it is important to consider that memantine presents a weak 
dopaminergic agonist with atropinic effects. Memantine 
should not be administered alongside compounds acting upon 
the same receptor (NMDA) system (amantadine, ketamine, 
dextromethorphan) due to the risk of pharmacotoxic 
psychosis.66 There is one published case report on a possible 
risk for the combination of memantine and phenytoin.67
Conclusion
Alzheimer patients present an increased risk of ADRs and 
drug–drug interaction ADRs due to several factors such as 
age, age of disease onset, the presence of multi-pharmaco-
therapy as well as disease-related CNS alterations that cause 
sensitization to the effects of psychotropic drugs. Although 
there are few studies of pharmacokinetic interaction related 
to Alzheimer patients, considering the potential hepatic 
effects, it is important to pay attention when prescribing 
drugs for patients who:97,98 1) take cytochrome inhibitors of 
CYP3A4 and CYP2D6; 2) take several cytochrome substrates 
that compete for the metabolic pathway; 3) present reduced 
glomerular filtration rate; and 4) are affected by hepatic dis-
ease affecting metabolic functions. Another pharmacokinetic 
interaction that could affect memantine plasma concentration 
profile in AD patients is represented by drugs that may alter 
the urinary pH.
One of the most important pharmacodynamic interac-
tions, based on their opposing mechanisms of action, is repre-
sented by the concomitant use of AChEIs and anticholinergic 
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drugs that results in pharmacological antagonism.72 The 
anticholinergic effect is a feature of several drugs such as 
antipsychotics, antidepressants, antihistamines, bronchodila-
tors, and drugs for urinary incontinence that are frequently 
prescribed to Alzheimer patients, especially to those with 
behavioral and psychotic symptoms. Finally, in this setting, 
we have to consider the cardiovascular adverse reaction 
related to the drugs, keeping in mind the possible alteration 
in the rhythm and the QT.
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